Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients Patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine. [Press release from Dana-Farber Cancer Institute discussing the online prepublication in the Journal of Clinical Oncology]
Biochemical Profile May Help Diagnose and Determine Aggressiveness of Prostate Cancer Researchers report how spectroscopic analysis of the biochemical makeup of prostate glands accurately identified the location of tissue confirmed to be malignant by conventional pathology. [Press release from Massachusetts General Hospital discussing the online prepublication in Science Translational Medicine]
Inherited Genetic Variant Predisposes to Aggressive but Not Indolent Prostate Cancer This study demonstrates that inherited variants predisposing to aggressive but not indolent prostate cancer exist in the genome, and suggests that the clinical potential of such variants as potential early markers for risk of aggressive prostate cancer should be evaluated. [Proc Nat Acad Sci]
Prostate Cancer Treatment for Economically Disadvantaged Men The authors compared the types of treatments prostate cancer patients received from county hospitals and private providers as part of a statewide public assistance program. [Cancer]
Poniard Shares Dented by Picoplatin Comparison Data Shares of a cash-strapped Poniard Pharmaceuticals took a pounding as investors reacted to the news that its cancer therapy picoplatin demonstrated a lower overall survival rate for colorectal cancer patients when compared to a standard combination treatment in a mid-stage trial. [Fierce Biotech]
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit
here to post your career opportunities.
